Literature DB >> 21267346

Immunization: primary prevention par excellence.

M V Fast.   

Abstract

Immunizing agents and vaccination programs have had a major impact on the health and longevity of our population. The continuation of established programs and the introduction of new programs will undoubtedly remain an integral part of our primary prevention activities. Decisions on the universal need for earlier immunizing agents were relatively straightforward, since most were directed at agents which were extremely communicable, and all were active against agents to which the population was fairly uniformly exposed. Because several of the "newer" vaccines do not meet these criteria, decisions on their use must be reviewed and may need to be based on other criteria. All decisions must take into account the risks and benefits of the vaccines. It must also be accepted that not all beneficial vaccines will necessarily become a part of universal immunization programs.

Year:  1987        PMID: 21267346      PMCID: PMC2218282     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  9 in total

1.  Prevention of pneumococcal pneumonia by vaccination.

Authors:  R Austrian; R M Douglas; G Schiffman; A M Coetzee; H J Koornhof; S Hayden-Smith; R D Reid
Journal:  Trans Assoc Am Physicians       Date:  1976

2.  Protective efficacy of pneumococcal polysaccharide vaccines.

Authors:  P Smit; D Oberholzer; S Hayden-Smith; H J Koornhof; M R Hilleman
Journal:  JAMA       Date:  1977-12-12       Impact factor: 56.272

3.  Polyvalent pneumococcal-polysaccharide immunization of patients with sickle-cell anemia and patients with splenectomy.

Authors:  A J Ammann; J Addiego; D W Wara; B Lubin; W B Smith; W C Mentzer
Journal:  N Engl J Med       Date:  1977-10-27       Impact factor: 91.245

4.  Efficacy of hepatitis B vaccine in prevention of early HBsAg carrier state in children. Controlled trial in an endemic area (Senegal).

Authors:  P Maupas; J P Chiron; F Barin; P Coursaget; A Goudeau; J Perrin; F Denis; I D Mar
Journal:  Lancet       Date:  1981-02-07       Impact factor: 79.321

5.  Prevention of Hemophilus influenzae type b bacteremic infections with the capsular polysaccharide vaccine.

Authors:  H Peltola; H Käyhty; M Virtanen; P H Mäkelä
Journal:  N Engl J Med       Date:  1984-06-14       Impact factor: 91.245

6.  Immunization of US children with Hemophilus influenzae type b polysaccharide vaccine. A cost-effectiveness model of strategy assessment.

Authors:  S L Cochi; C V Broome; A W Hightower
Journal:  JAMA       Date:  1985-01-25       Impact factor: 56.272

7.  Controversy in the detection of disease.

Authors:  D L Sackett; W W Holland
Journal:  Lancet       Date:  1975-08-23       Impact factor: 79.321

Review 8.  Vaccine prevention of Haemophilus influenzae type b disease: past, present and future.

Authors:  S L Cochi; C V Broome
Journal:  Pediatr Infect Dis       Date:  1986 Jan-Feb

Review 9.  Pneumococcal vaccine: clinical efficacy and effectiveness.

Authors:  J S Schwartz
Journal:  Ann Intern Med       Date:  1982-02       Impact factor: 25.391

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.